EUVIMEDEuropean Health Evidence
Uhr 10/10Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence

Adela G. Buciuc, Mark S. Gold, Brian Fuehrlein

Addiction & Prevention · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Substance use disorders (SUDs) are a leading cause of preventable death worldwide, yet approved pharmacotherapies exist for only three of them: alcohol, tobacco, and opioid use disorders. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), established in metabolic medicine, are candidates for repurposing across multiple SUDs. This review synthesizes preclinical mechanistic evidence, pharmacoepidemiologic data, and randomized trials, comprehensively for human studies and selectively for preclinical work establishing circuit-level mechanisms. GLP-1 RAs attenuate the peak amplitude and frequency of drug-evoked dopamine release in the nucleus accumbens through shared mesolimbic mechanisms while engaging substance-specific circuits, including the lateral septum for alcohol and psychostimulants and the medial habenula–interpeduncular pathway for nicotine. Evidence from CB1–incretin interaction studies suggests a distinct rationale for cannabis use disorder, in which GLP-1 RA administration may correct a drug-induced suppression of incretin tone; this framing is theoretical and has not been tested against addiction endpoints. Clinical evidence is most robust for alcohol use disorder, where convergent pharmacoepidemiologic signals and the SEMALCO randomized trial demonstrate efficacy in individuals with comorbid obesity; data for opioid, tobacco, cocaine, and cannabis use disorders remain limited. Translational barriers include dose–response relationships that remain uncharacterized because no trial has performed dose-ranging against an addiction endpoint, safety concerns in patients with eating pathology, and metabolic phenotype as a moderator, with directionally opposite effects across body mass index strata. Whether GLP-1 RAs achieve transdiagnostic utility will likely depend on patient selection and agent choice, but no validated selection criteria exist and this remains a hypothesis to be tested.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Adela G. Buciuc, Mark S. Gold, Brian Fuehrlein
Quelle
Addiction & Prevention
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
3043-0429
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Adela G. Buciuc, Mark S. Gold, Brian Fuehrlein (2026). Glucagon-like Peptide-1 Receptor Agonists for Substance Use Disorders: Comprehensive Review of Circuit Mechanisms and Clinical Evidence. Addiction & Prevention. https://doi.org/10.3390/addictprev1010007
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1